OBJECTIVES: The Patient Assessment, Care & Education (PACE) SystemTM was designed to address the persistent problem of under-identification and treatment of chemotherapy-related symptoms. The PACE SystemTM uses a pen-based e/Tablet that operates off a wireless network. Cancer Support NetworkTM on the e/Tablet provides educational materials to patients in text, video, audio, and graphic format. The PACE System™ also administers the Patient Care MonitorTM, a psychometrically validated, patient-reported symptom severity screening scale that generates a real-time, point-of-care report for the provider. The aim of the study was determined provider and patient opinions of the PACE System™ and to determine whether symptom assessment rates increased after the PACE System was implemented METHODS: Ninety-two providers (i.e., physicians, nurse practitioners, physician assistants) at 16 community oncology clinics were surveyed about their experiences with the PACE System™ In addition, 100 patients at two community oncology clinics were surveyed about their perceptions of the PACE System™ . At two oncology clinics 100 patient charts were abstracted in the year prior to implementation of the PACE system and in the year after the implementation the PACE system to determine symptom assessment rates. RESULTS: The majority of patients reported that they were generally satisfied with the PCM (55%). Slightly more than half indicated that it helped them to remember symptoms, although only 44% said it encourage them to discuss their symptoms. 91% of respondents said the e/tablet was easy to use. The majority of providers thought that the PCM increased the frequency with which symptoms were identified and treated. The results from the chart review show statistically significant increases in the assessment rates for depression, pain, and fatigue after the PACE system was implemented. CONCLUSION: The PACE system appears to be a promising approach to addressing the widespread problem of under-identification and under-treatment of symptoms in patients undergoing cancer treatment.